TELL ME MORE

ABOUT THIS CLINICAL TRIAL FOR GLYCEMIC CONTROL IN ADULTS

A phase 2, parallel-group, double-Blind, placebo-controlled study to investigate the effect of an investigational medicine on glycemic control compared with placebo in adult participants with type 2 diabetes

Clinical Trial for Diabetes in Adults with CV Risk

Study Location(s): Bowling Green, KY

Poor glycemic control, which is the inability to maintain blood glucose levels within the recommended range and leads to elevated blood sugar levels over time, is a significant risk factor for the development and progression of diabetes-related complications. Glycemic control is central in diabetes management, yet complex and challenging to achieve; it can be affected by various factors. Maintaining blood glucose concentration is essential to avoid severe complications.

T2DM is a chronic progressive disease that significantly impacts morbidity and mortality worldwide. The global prevalence of diabetes in adults (20–79 years) is high and constantly rising. (source: NIH – National Institute of Health)

The purpose of this study is to measure the effect of an investigational medicine on glycemic control and weight reduction compared with placebo tablets in adult participants with T2D.

Potential patients must be 18 to 75 years with a clinical diagnosis of T2D for at least 6 months prior to screening, have an HbA1c value of ≥7.0% and ≤10.5%, and have stable body weight for 3 months prior to study with a BMI 25 kg/m2 at Visit 1. Other criteria may apply as well.

There is no cost to participate.  Volunteers receive no cost investigational medicine and no cost health exams.  No insurance needed.  Reimbursement for time and travel up is TBD.

Pin It on Pinterest